Evidence map›Paper›PMID 26468198›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2015

Enhanced Functional Activity of the Cannabinoid Type-1 Receptor Mediates Adolescent Behavior.

Miriam Schneider, Fernando Kasanetz, Diane L Lynch, Chris M Friemel, Olivier Lassalle, Dow P Hurst, Frauke Steindel, Krisztina Monory, Carola Schäfer, Isabelle Miederer and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
5.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Genetic Tools in Rodents to Study Cannabinoid Functions.Current topics in behavioral neurosciences · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Combinatorial approaches for treating neuropsychiatric social impairment.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2022
    Review
  8. Article
  9. Early Consumption of Cannabinoids: From Adult Neurogenesis to Behavior.International journal of molecular sciences · 2021
    Review
  10. Which came first: Cannabis use or deficits in impulse control?Progress in neuro-psychopharmacology & biological psychiatry · 2021
    Review
  11. Article
  12. Neurobiology of cannabinoid receptor signaling
.Dialogues in clinical neuroscience · 2020
    Review
  13. Article
  14. Adolescent ΔFrontiers in psychiatry · 2020
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 3 countries.

Miriam SchneiderInstitute of Psychopharmacology and Research Group Developmental Neuropsychopharmacology, Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, 68159 Mannheim, Germany, miriam.schneider@zi-mannheim.de.
Fernando KasanetzINSERM, Neurocentre Magendie, and University of Bordeaux, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, U862, F-33000 Bordeaux, France.
Diane L LynchCenter for Drug Discovery, Department of Chemistry and Biochemistry, University of North Carolina, Greensboro, North Carolina 27402.
Chris M FriemelResearch Group Developmental Neuropsychopharmacology, Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, 68159 Mannheim, Germany.ORCID http://orcid.org/0000-0002-0537-0970
Olivier LassalleINSERM, U901, Marseille 13009, France, Université de la Méditerranée, UMR S901 Aix-Marseille 2, France, INMED, Marseille 13009, France.ORCID http://orcid.org/0000-0002-8523-1988
Dow P HurstCenter for Drug Discovery, Department of Chemistry and Biochemistry, University of North Carolina, Greensboro, North Carolina 27402.
Frauke SteindelInstitute of Physiological Chemistry, University Medical Center of the Johannes Gutenberg University Mainz, 55128 Mainz, Germany.
Krisztina MonoryInstitute of Physiological Chemistry, University Medical Center of the Johannes Gutenberg University Mainz, 55128 Mainz, Germany.ORCID http://orcid.org/0000-0002-1548-7718
Carola SchäferDepartment of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, 68159 Mannheim, Germany, Department of Psychiatry and Psychotherapy, University of Cologne, 50924 Cologne, Germany, and.
Isabelle MiedererDepartment of Nuclear Medicine, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
F Markus LewekeDepartment of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, 68159 Mannheim, Germany.ORCID http://orcid.org/0000-0002-8163-195X
Mathias SchreckenbergerDepartment of Nuclear Medicine, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
Beat LutzInstitute of Physiological Chemistry, University Medical Center of the Johannes Gutenberg University Mainz, 55128 Mainz, Germany.
Patricia H ReggioCenter for Drug Discovery, Department of Chemistry and Biochemistry, University of North Carolina, Greensboro, North Carolina 27402.
Olivier J ManzoniINSERM, U901, Marseille 13009, France, Université de la Méditerranée, UMR S901 Aix-Marseille 2, France, INMED, Marseille 13009, France.
Rainer SpanagelInstitute of Psychopharmacology and.
Johannes Gutenberg University Mainz · DEHeidelberg University · DEUniversity of North Carolina at Greensboro · USInserm · FRChild Psychopharmacology Institute · USUniversité de Bordeaux · FRUniversity of Cologne · DE

Funding

Molecular Determinants of Cannabinoid ActivityR01DA003934 · NIDA · UNIVERSITY OF NORTH CAROLINA GREENSBORO · PI REGGIO, PATRICIA HODAPP · 1985 to 2019
$5.6M
Senior Scientist Award: Molecular Determinants for Cannabinoid ActivityK05DA021358 · NIDA · UNIVERSITY OF NORTH CAROLINA GREENSBORO · PI REGGIO, PATRICIA HODAPP · 2007 to 2016
$1.3M
NIDA NIH HHS K05 DA021358NIDA NIH HHS KO5 DA021358NIDA NIH HHS R01 DA003934
6 · The paper itself

Abstract

Adolescence is characterized by drastic behavioral adaptations and comprises a particularly vulnerable period for the emergence of various psychiatric disorders. Growing evidence reveals that the pathophysiology of these disorders might derive from aberrations of normal neurodevelopmental changes in the adolescent brain. Understanding the molecular underpinnings of adolescent behavior is therefore critical for understanding the origin of psychopathology, but the molecular mechanisms that trigger adolescent behavior are unknown. Here, we hypothesize that the cannabinoid type-1 receptor (CB1R) may play a critical role in mediating adolescent behavior because enhanced endocannabinoid (eCB) signaling has been suggested to occur transiently during adolescence. To study enhanced CB1R signaling, we introduced a missense mutation (F238L) into the rat Cnr1 gene that encodes for the CB1R. According to our hypothesis, rats with the F238L mutation (Cnr1(F238L)) should sustain features of adolescent behavior into adulthood. Gain of function of the mutated receptor was demonstrated by in silico modeling and was verified functionally in a series of biochemical and electrophysiological experiments. Mutant rats exhibit an adolescent-like phenotype during adulthood compared with wild-type littermates, with typical high risk/novelty seeking, increased peer interaction, enhanced impulsivity, and augmented reward sensitivity for drug and nondrug reward. Partial inhibition of CB1R activity in Cnr1(F238L) mutant rats normalized behavior and led to a wild-type phenotype. We conclude that the activity state and functionality of the CB1R is critical for mediating adolescent behavior. These findings implicate the eCB system as an important research target for the neuropathology of adolescent-onset mental health disorders. SIGNIFICANCE STATEMENT: We present the first rodent model with a gain-of-function mutation in the cannabinoid type-1 receptor (CB1R). Adult mutant rats exhibit an adolescent-like phenotype with typical high risk seeking, impulsivity, and augmented drug and nondrug reward sensitivity. Adolescence is a critical period for suboptimal behavioral choices and the emergence of neuropsychiatric disorders. Understanding the basis of these disorders therefore requires a comprehensive knowledge of how adolescent neurodevelopment triggers behavioral reactions. Our behavioral observations in adult mutant rats, together with reports on enhanced adolescent CB1R signaling, suggest a pivotal role for the CB1R in an adolescent brain as an important molecular mediator of adolescent behavior. These findings implicate the endocannabinoid system as a notable research target for adolescent-onset mental health disorders.

Indexed as

AdolescentAdolescent BehaviorAge FactorsAnimalsBehavior, AnimalBrainCannabinoid Receptor AntagonistsCocaineCorpus StriatumEndocannabinoidsExploratory BehaviorGuanosine 5'-O-(3-Thiotriphosphate)HumansIn Vitro TechniquesMaleMaze LearningCannabinoid Receptor AntagonistsCNR1 protein, mouseCocaineEndocannabinoidsGuanosine 5'-O-(3-Thiotriphosphate)Receptor, Cannabinoid, CB1Sulfur IsotopesadolescenceCB1 receptorendocannabinoidsENU mutagenesisreward processingrisk seeking

Identifiers

PMID26468198
PMCPMC4604232
OpenAlexW2335996372

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.